FDA Approves Roche’s Susvimo as the First and Only Continuous-Delivery Treatment for Diabetic Retinopathy, Offering Nine-Month Dosing Durability In a significant advancement for patients suffering from diabetic retinopathy (DR), the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab…
A Call for Change: Ensuring Access and Insurance Coverage for People Living with Obesity In recent months, abrupt changes to insurance coverage for obesity management medications have placed thousands of Americans living with obesity in an impossible situation. Many now…
Merck Unveils Positive Phase 2 Results for Enpatoran, Showing Significant Reduction in Disease Activity in Patients with Cutaneous and Systemic Lupus with Active Rash Merck, a global leader in science and technology, has announced compelling new clinical data from its…
Roche’s Genentech Faces Setback as FDA Advisory Committee Rejects Columvi Expansion Proposal The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) delivered a significant blow to Genentech, a subsidiary of Roche, by voting overwhelmingly against the company’s…
Charting a Healthier Future: A Comprehensive Analysis of Economic and Commercial Determinants of Health in Small Island Developing States A newly released technical paper by the World Health Organization (WHO) marks a pivotal advancement in the global response to noncommunicable…
Alnylam Pharmaceuticals Unveils 2024 Corporate Responsibility Report, Showcasing Impact Across ESG Pillars Alnylam Pharmaceuticals, the industry leader in RNA interference (RNAi) therapeutics, has published its 2024 Corporate Responsibility Report, reaffirming its commitment to science, sustainability, equity, and ethical business conduct.…
BioNTech Strengthens Partnership with UK Government to Significantly Expand Regional Research and Development Efforts BioNTech , a leading biotechnology firm recognized globally for its pioneering work in mRNA technology and immunotherapies, today announced a landmark agreement between its UK subsidiary,…
CRISPR Breakthrough in a Single Infant Sheds Light on the Urgent Crisis Facing Millions with Ultra-Rare Diseases A groundbreaking success story involving a custom-made CRISPR gene-editing therapy has given new hope to the families of children diagnosed with ultra-rare diseases—but…
Aetna Better Health of Illinois Invests $20.4 Million to Strengthen Value-Based Care and Improve Health Equity Across the State Aetna Better Health® of Illinois, a Medicaid managed care plan and subsidiary of CVS Health® (NYSE: CVS), has made a landmark…
Daiichi Sankyo and Merck Launch Phase 3 IDeate-Esophageal01 Trial of Ifinatamab Deruxtecan in Advanced Esophageal Squamous Cell Carcinoma Daiichi Sankyo and Merck have officially initiated dosing in their pivotal Phase 3 clinical trial, named IDeate-Esophageal01, marking a significant step forward…
One World for Health: Inside the 78th World Health Assembly and the Future of Global Public Health From May 19 to 27, 2025, Geneva, Switzerland, will once again become the epicenter of global health governance as it hosts the Seventy-eighth…
WHO and Universal Postal Union Launch Global Initiative to Expand Access to Eye Care Through Postal Networks In a groundbreaking move to address the global burden of vision impairment, the World Health Organization (WHO) has announced a strategic partnership with…
